DOCSLIB.ORG

Pituitary Tumor Transforming Gene Interacts with Sp1 to Modulate G1/S Cell Phase Transition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pituitary Tumor Transforming Gene Interacts with Sp1 to Modulate G1/S Cell Phase Transition Oncogene (2007) 26, 5596–5605 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc ORIGINAL ARTICLE Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition Y Tong, Y Tan, C Zhou and S Melmed Department of Medicine, Cedars-Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Pituitary tumor transforming gene (PTTG1) was isolated et al., 2001, 2003; Chesnokova et al., 2005). Disrupted from rat pituitary tumor cells, and subsequently identified PTTG1 results in insulinopenic diabetes in adult mice, as a securin protein as well as a transcription factor. We with male-selective hyperglycemia (Wang et al., 2003). show here a global transcriptional effect of PTTG1 in Enhanced PTTG1 abundance correlates with tumor human choriocarcinoma JEG-3 cells by simultaneously development and size (McCabe et al., 2003). PTTG1 is assessing 20 000 gene promoters using chromatin immu- induced in the early stages of estrogen-induced rat noprecipitation (ChIP)-on-Chip experiments. Seven hun- prolactinoma pathogenesis (Heaney et al., 1999) and has dred and forty-six gene promoters (Po0.001) were found been suggested as a prognostic marker for differentiated enriched, with functions relating to cell cycle, metabolic thyroid cancer, lymph node invasion and breast cancer controland signaltransduction. Significant interaction recurrence (Solbach et al., 2004), and colon cancer between PTTG1 and Sp1 (Po0.000001) was found by invasiveness and vascularity (Heaney et al., 2000). transcriptionalpattern analysis of ChIP data and further Mechanisms of PTTG1 action include binding to p53, confirmed by immunoprecipitation and pull-down assays. inhibiting its transcriptional activity and interacting PTTG1 acts coordinately with Sp1 to induce cyclin D3 with Ku, the regulatory subunit of DNA-dependent expression Bthreefold, and promotes G1/S-phase transi- protein kinase (Wang and Melmed, 2000; Pei, 2000), tion independently of p21. PTTG1 deletion was also activating c-Myc (Pei, 2001) and basic fibroblast growth protective for anchorage-independent cell colony forma- factor (bFGF) (Chien and Pei, 2000), and acting as a tion. The results show that PTTG1 exhibits properties of securin to inhibit separase, which cleaves sister chroma- a global transcription factor, and specifically modulates tids with fidelity during mitosis (Zou et al., 1999). the G1/S-phase transition by interacting with Sp1. This However, it is unclear how PTTG1 overexpression novelsignaling pathway may be required for PTTG1 mediates tumorigenesis and little is known of the transforming activity. functional mechanisms underlying cellular PTTG1 Oncogene (2007) 26, 5596–5605; doi:10.1038/sj.onc.1210339; action. published online 12 March 2007 Because of widespread PTTG1 functions, we surveyed PTTG1 effects on 20 000 gene promoters. We show here Keywords: PTTG1; pituitary; cell cycle that PTTG1 acts as a global transcription factor, and specifically modulates the G1/S-phase transition by interacting with Sp1, which may underlie its transform- ing activity. Introduction Results Pituitary tumor transforming gene (PTTG1) isolated ChIP-on-Chip experiments and microarray from rat pituitary tumor cells (Pei and Melmed, 1997), image analysis was subsequently identified as a securin protein (Zou The chromatin immunoprecipitation (ChIP)-on-Chip et al., 1999) and a transcription factor (Dominguez assay showed that 746 gene promoters (3.73% of all gene et al., 1998). It also plays a role in organ development promoters studied) were significantly enriched (P 0.001) and metabolism. PTTG1 is required for rat liver o among 20 000 genes by immunoprecipitation with PTTG1 regeneration, human fetal brain development (Boelaert antibody (Supplemental Data 2) and the remaining 13000 et al., 2003) and telencephalic neurogenesis (Tarabykin genes were used as background promoter set. The results et al., 2000). PTTG1-null mice exhibit testicular, splenic, of ChIP-on-Chip assay were confirmed by ChIP poly- pancreatic beta cell and pituitary hypoplasia (Wang merase chain reaction (PCR) as described (Li et al., 2003). Briefly, 19 gene promoters, including ATPAF1, Correspondence: Dr S Melmed, Academic Affairs, Room 2015, 8700 HUMCYT2A, C6orf102, KNTC1, COCH, PP2447, Beverly Blvd, Los Angeles, CA 90048, USA. E-mail: [email protected] CSNK2B, RAD51L3, EIF4B, RASGRF1, FLJ31153, Received 13October 2006; revised 5 January 2007; accepted 7 January RPL32, GABARAPL2, SREBF2, GALNT5, SUCLG2, 2007; published online 12 March 2007 GCDH, TNFRSF13C and GOLGA1, were selected and PTTG1 modulates G1/S phase transition Y Tong et al 5597 conventional ChIP PCR assay used to detect enrichment reported Myc/Max interaction partners TFIIB, Sp1, of the promoters in the immunoprecipitated chromatins. E2F and Ap-2 (Supplemental Data 3). The negative primers used were from the ChIP-IT Among the 746 enriched gene promoters, 618 were kit (Active Motif). The results showed that at least well characterized from the promoter sequence database 95% of the observed enriched genes are true positives (http://biowulf.bu.edu/zlab/PromoSer/promoser.html) (Figure 1a). and the corresponding sequences extracted for tran- scriptional motif analysis as stated above. Analysis of PTTG1 ChIP-on-Chip data and the background data Transcriptional pattern analysis sets revealed a significant interaction between PTTG1 The transcriptional pattern analysis as described in and Sp1 (Po0.000001) (Figure 1b). To further identify Materials and methods was then performed to unravel the binding location of SP1, the promoter sequence of transcriptional patterns yielded by the ChIP-on-Chip each gene in both the enriched and background results. This approach allowed us to test functional promoter set was evenly divided into 10 intervals, each relationships of PTTG1 with other transcription factors comprising 200 bp (from À1800 bp upstream to 200 bp and to identify transcriptional regulation modules downstream of transcription starting site (TSS)) and the controlling gene expression. The same transcriptional frequency of motif occurrence in each interval was pattern analysis was also applied to published c-Myc calculated and plotted in Figure 1c. The results show ChIP-on-Chip data (Li et al., 2003) and the results that the greatest difference of Sp1 binding location showed that the method appropriately identified between enriched and background promoter sets occurs a None Beads Anti-PTTGInput None Beads Anti-PTTGInput ATPAF1 HUMCYT2A C6orf102 KNTC1 COCH PP2447 CSNK2B RAD51L3 EIF4B RASGRF1 FLJ31153 RPL32 GABARAPL2 SREBF2 GALNT5 SUCLG2 GCDH TNFRSF13C GOLGA1 Negative primer b 45 c 40 0.4 Sp1 35 Sp1 0.35 30 0.3 PTTG1 enriched Background 25 0.25 20 0.2 15 Percentage 0.15 10 0.1 Number of promoter set 5 0.05 TSS 0 0 0.58 0.6 0.62 0.64 0.66 0.68 0.7 12345 678910 Frequency Interval Figure 1 ChIP-on-Chip and transcription pattern analysis. (a) Nineteen genes were randomly selected from the ChIP-on-Chip results. JEG-3chromatin was immunoprecipitated by PTTG1 antibody and regular PCR assay carried out using ChIP-IT kits (Active Motif) to detect and confirm promoter enrichment. All 19 gene promoters were confirmed as positive. (b) Transcription pattern analysis: frequency distribution of occurrence of the Sp1 motif in the 1000 randomly selected background promoter data sets. Solid red line represents frequency of occurrence of the Sp1 motif in the enriched promoter data set. Frequency of Sp1 in the PTTG1-enriched set was significantly (Po0.000001) higher than expected by chance. (c) Frequency distribution of occurrence of the Sp1 motif along the promoter sequence (10 intervals, each 200 bp long, ranging from À1800 bp to 200 bp) for both the enriched and background promoter set (containing the remaining non-enriched promoters). The largest difference appeared to be À200 bp from the TSS. Oncogene PTTG1 modulates G1/S phase transition Y Tong et al 5598 at À200 to 0 bp, suggesting that the Sp1 binding site may PTTG1 regulates Sp1 binding to its motif and colocalizes approximate the TSS position (Figure 1c). with Sp1 on cyclin D3 promoter We further examined Sp1 binding to its motif in the presence of PTTG1 and PTTG1 fragments. In PTTG1 interacts with Sp1 Figure 3a1, we show that PTTG1 and the consensus Sp1 We used agarose-conjugated Sp1 antibody to immuno- binding sequence in the absence of Sp1 protein did not precipitate the Sp1 complex, and as shown in Figure 2a, cause a shift, suggesting that PTTG1 does not bind the PTTG1 associated with Sp1 in both JEG-3and HCT116 Sp1 binding sequence. Incubation of Sp1 with the Sp1 cells, suggesting that they interact in vivo. We confirmed binding sequence is shown to shift the band, suggesting PTTG1 and Sp1 interaction by His-tag pulldown assay that Sp1 binds to this sequence as expected. Incubation and further mapped their interaction domains using of Sp1, PTTG1 and the consensus Sp1 binding sequence poly-His-tagged PTTG1, Sp1 and their respective resulted in both a shifted and a super-shifted band. The fragments (Figure 2b and c). The PTTG1 N-terminus shifted band likely comprises Sp1 and consensus Sp1 (aa 1–120) and Sp1 C-terminus (aa 401–785) bind to the binding sequence complex. As only two proteins are full-length protein, respectively, suggesting the location present in this system, the super-shifted bands appear of protein domains required for their physical interac- to reflect a formation of PTTG1-Sp1-consensus Sp1 tions (Figure 2b, c and d). binding sequence complexes. abSp1 and its fragments Binding to PTTG1 1 400 Sp1.F1 - 301 500 - Sp1.F2 Input Neg IgG Sp1 Ab 401 785 + Sp1.F3 JEG-3 1 785 Sp1 + PTTG1 HCT116 Control Sp1.F1 Sp1.F2 Sp1.F3 Sp1 Input PTTG1 c PTTG1 and its fragments Binding to Sp1 1 120 + PTTG1.F1 101 202 PTTG1.F2 - 1 202 PTTG1 + Control PTTG1-F1PTTG1-F2PTTG1 Input Sp1 d Sp1 N C Interactio PTTG1 N C Sp box Transactivating DNA binding Zinc finger Ken box SH-3 binding D box Figure 2 PTTG1 interacts with Sp1.
Load more

Recommended publications
  • Identification of Novel Biomarkers and Candidate Small Molecule Drugs in Non-Small-Cell Lung Cancer by Integrated Microarray Analysis
    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis This article was published in the following Dove Press journal: OncoTargets and Therapy Qiong Wu1,2,* Background: Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer Bo Zhang1,2,* morbidity and mortality worldwide. In the present study, we identified novel biomarkers Yidan Sun3 associated with the pathogenesis of NSCLC aiming to provide new diagnostic and therapeu- Ran Xu1 tic approaches for NSCLC. Xinyi Hu4 Methods: The microarray datasets of GSE18842, GSE30219, GSE31210, GSE32863 and Shiqi Ren4 GSE40791 from Gene Expression Omnibus database were downloaded. The differential Qianqian Ma5 expressed genes (DEGs) between NSCLC and normal samples were identified by limma Chen Chen6 package. The construction of protein–protein interaction (PPI) network, module analysis and Jian Shu7 enrichment analysis were performed using bioinformatics tools. The expression and prog- Fuwei Qi7 nostic values of hub genes were validated by GEPIA database and real-time quantitative fi Ting He7 PCR. Based on these DEGs, the candidate small molecules for NSCLC were identi ed by the CMap database. Wei Wang2 Results: A total of 408 overlapping DEGs including 109 up-regulated and 296 down- Ziheng Wang2 regulated genes were identified; 300 nodes and 1283 interactions were obtained from the 1 Medical School of Nantong University, PPI network. The most significant biological process and pathway enrichment of DEGs were Nantong 226001, People’s Republic of China; 2The Hand Surgery Research Center, response to wounding and cell adhesion molecules, respectively.
    [Show full text]
  • TF Activation Profiling Plate Array II Signosis, Inc
    Signosis, Inc. Innovative Plate Assay Solutions TF Activation Profiling Plate Array II Catalog Number: FA-1002 (For Research Use Only) Introduction Materials Provided with the Kit Transcription factors (TFs) are a group of cellular proteins that play essential roles in regulating gene Component Qty Store at expression. They act as sensors to monitor cellular 96-Well Plates (with 2 RT changes and convert signals into gene expression. aluminum adhesive seal) Often, a specific cellular signal pathway can activate Isolation Columns 2 RT multiple TFs. The expression of a specific gene can Elution Buffer 400µL RT also be under the control of multiple TFs. Thus, TF Plate Hybridization Buffer 20mL RT monitoring the activation of multiple TFs 5X Plate Hybridization Wash 60mL RT simultaneously is critical to understanding the Buffer molecular mechanism of cellular regulation underlying 5X Detection Wash Buffer 60mL RT cell signaling and gene expression. Signosis, Inc.’s TF Blocking Buffer 60mL RT Activation Profiling Plate Array II is used for Filter Wash Buffer 5mL 4°C monitoring 96 different TFs simultaneously from one Filter Binding Buffer 1mL 4°C sample. Substrate A 2mL 4°C Substrate B 2mL 4°C Principle of the assay Streptavidin-HRP Conjugate 40µL 4°C Substrate Dilution Buffer 16mL 4°C Signosis, Inc.’s TF Activation Profiling Plate Array II TF Binding Buffer Mix 60µL -20°C is used for monitoring the activation of multiple TFs TF Probe Mix II 20µL -20°C simultaneously. With this technology a series of biotin-labeled probes are made based on the consensus sequences of TF DNA-binding sites.
    [Show full text]
  • Interindividual Regulation of the BCRP/ABCG2 Transporter in Term Human Placentas
    DMD Fast Forward. Published on January 31, 2018 as DOI: 10.1124/dmd.117.079228 This article has not been copyedited and formatted. The final version may differ from this version. DMD #79228 Title Page Interindividual Regulation of the BCRP/ABCG2 Transporter in Term Human Placentas Kristin M Bircsak, Jamie E Moscovitz, Xia Wen, Faith Archer, Poi Yu Sofia Yuen, Moiz Mohammed, Naureen Memon, Barry I Weinberger, Laura M Saba, Anna M Vetrano, Lauren M Aleksunes Downloaded from Department of Pharmacology and Toxicology, Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy, Piscataway, NJ, USA (K.M.B., J.E.M., X.W., L.M.A.), dmd.aspetjournals.org Department of Pediatrics, Rutgers University Robert Wood Johnson Medical School, New Brunswick, NJ, USA (F.A., P.Y.S.Y, M.M., N.M., A.M.V.), Hofstra Northwell School of Medicine, Cohen Children’s Medical Center of New York, New Hyde Park, NY, USA (B.I.W.), at ASPET Journals on October 2, 2021 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA (L.S.), Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ, USA (L.M.A.), Lipid Center, Rutgers, The State University of New Jersey, Piscataway, NJ, USA (L.M.A.) 1 DMD Fast Forward. Published on January 31, 2018 as DOI: 10.1124/dmd.117.079228 This article has not been copyedited and formatted. The final version may differ from this version. DMD #79228 Running Title Page Running title: Interindividual
    [Show full text]
  • Early Growth Response 1 Regulates Hematopoietic Support and Proliferation in Human Primary Bone Marrow Stromal Cells
    Hematopoiesis SUPPLEMENTARY APPENDIX Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells Hongzhe Li, 1,2 Hooi-Ching Lim, 1,2 Dimitra Zacharaki, 1,2 Xiaojie Xian, 2,3 Keane J.G. Kenswil, 4 Sandro Bräunig, 1,2 Marc H.G.P. Raaijmakers, 4 Niels-Bjarne Woods, 2,3 Jenny Hansson, 1,2 and Stefan Scheding 1,2,5 1Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Lund Stem Cell Center, Depart - ment of Laboratory Medicine, Lund University, Lund, Sweden; 3Division of Molecular Medicine and Gene Therapy, Department of Labora - tory Medicine, Lund University, Lund, Sweden; 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands and 5Department of Hematology, Skåne University Hospital Lund, Skåne, Sweden ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.216648 Received: January 14, 2019. Accepted: July 19, 2019. Pre-published: August 1, 2019. Correspondence: STEFAN SCHEDING - [email protected] Li et al.: Supplemental data 1. Supplemental Materials and Methods BM-MNC isolation Bone marrow mononuclear cells (BM-MNC) from BM aspiration samples were isolated by density gradient centrifugation (LSM 1077 Lymphocyte, PAA, Pasching, Austria) either with or without prior incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). BM-MNCs from fetal long bones and adult hip bones were isolated as reported previously 1 by gently crushing bones (femora, tibiae, fibulae, humeri, radii and ulna) in PBS+0.5% FCS subsequent passing of the cell suspension through a 40-µm filter.
    [Show full text]
  • A Dissertation Entitled the Androgen Receptor
    A Dissertation entitled The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit Submitted to the Graduate Faculty as partial fulfillment of the requirements for the PhD Degree in Biomedical science Dr. Manohar Ratnam, Committee Chair Dr. Lirim Shemshedini, Committee Member Dr. Robert Trumbly, Committee Member Dr. Edwin Sanchez, Committee Member Dr. Beata Lecka -Czernik, Committee Member Dr. Patricia R. Komuniecki, Dean College of Graduate Studies The University of Toledo August 2011 Copyright 2011, Mesfin Gonit This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit As partial fulfillment of the requirements for the PhD Degree in Biomedical science The University of Toledo August 2011 Prostate cancer depends on the androgen receptor (AR) for growth and survival even in the absence of androgen. In the classical models of gene activation by AR, ligand activated AR signals through binding to the androgen response elements (AREs) in the target gene promoter/enhancer. In the present study the role of AREs in the androgen- independent transcriptional signaling was investigated using LP50 cells, derived from parental LNCaP cells through extended passage in vitro. LP50 cells reflected the signature gene overexpression profile of advanced clinical prostate tumors. The growth of LP50 cells was profoundly dependent on nuclear localized AR but was independent of androgen. Nevertheless, in these cells AR was unable to bind to AREs in the absence of androgen.
    [Show full text]
  • Supplemental Table 1. Primers and Probes for RT-Pcrs
    Supplemental Table 1. Primers and probes for RT-PCRs Gene Direction Sequence Quantitative RT-PCR E2F1 Forward Primer 5’-GGA TTT CAC ACC TTT TCC TGG AT-3’ Reverse Primer 5’-CCT GGA AAC TGA CCA TCA GTA CCT-3’ Probe 5’-FAM-CGA GCT GGC CCA CTG CTC TCG-TAMRA-3' E2F2 Forward Primer 5'-TCC CAA TCC CCT CCA GAT C-3' Reverse Primer 5'-CAA GTT GTG CGA TGC CTG C-3' Probe 5' -FAM-TCC TTT TGG CCG GCA GCC G-TAMRA-3' E2F3a Forward Primer 5’-TTT AAA CCA TCT GAG AGG TAC TGA TGA-3’ Reverse Primer 5’-CGG CCC TCC GGC AA-3’ Probe 5’-FAM-CGC TTT CTC CTA GCT CCA GCC TTC G-TAMRA-3’ E2F3b Forward Primer 5’-TTT AAA CCA TCT GAG AGG TAC TGA TGA-3’ Reverse Primer 5’-CCC TTA CAG CAG CAG GCA A-3’ Probe 5’-FAM-CGC TTT CTC CTA GCT CCA GCC TTC G-TAMRA-3’ IRF-1 Forward Primer 5’-TTT GTA TCG GCC TGT GTG AAT G-3’ Reverse Primer 5’-AAG CAT GGC TGG GAC ATC A-3’ Probe 5’-FAM-CAG CTC CGG AAC AAA CAG GCA TCC TT-TAMRA-3' IRF-2 Forward Primer 5'-CGC CCC TCG GCA CTC T-3' Reverse Primer 5'-TCT TCC TAT GCA GAA AGC GAA AC-3' Probe 5'-FAM-TTC ATC GCT GGG CAC ACT ATC AGT-TAMRA-3' TBP Forward Primer 5’-CAC GAA CCA CGG CAC TGA TT-3’ Reverse Primer 5’-TTT TCT TGC TGC CAG TCT GGA C-3’ Probe 5’-FAM-TGT GCA CAG GAG CCA AGA GTG AAG A-BHQ1-3’ Primers and Probes for quantitative RT-PCRs were designed using the computer program “Primer Express” (Applied Biosystems, Foster City, CA, USA).
    [Show full text]
  • Pituitary Tumor Transforming Gene 1 Regulates Aurora Kinase a Activity
    Oncogene (2008) 27, 6385–6395 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $32.00 www.nature.com/onc ORIGINAL ARTICLE Pituitary tumor transforming gene 1 regulates Aurora kinase A activity Y Tong, A Ben-Shlomo, C Zhou, K Wawrowsky and S Melmed Department of Medicine, Cedars-Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Pituitary tumor transforming gene 1 (PTTG1),a pathogenesis of estrogen-induced rat prolactinomas transforming gene highly expressed in several cancers,is (Heaney et al., 1999), and has been suggested as a a mammalian securin protein regulating both G1/S and prognostic marker for thyroid, breast (Solbach et al., G2/M phases. Using protein array screening,we showed 2004)and colon cancer invasiveness (Heaney et al., PTTG1 interacting with Aurora kinase A (Aurora-A), 2000). PTTG and HTLV-1 Tax exhibit a cooperative and confirmed the interaction using co-immunoprecipita- transforming activity (Sheleg et al., 2007), whereas small tion,His-tagged pull-down assays and intracellular interfering RNA (siRNA)directed against PTTG immunofluorescence colocalization. PTTG1 transfection suppressed lung cancer growth in nude mice (Kakar into HCT116 cells prevented Aurora-A T288 autopho- and Malik, 2006)and was also proposed as a subcellular sphorylation,inhibited phosphorylation of the histone H3 therapy for ovarian cancer (El-Naggar et al., 2007). Aurora-A substrate and resulted in abnormally condensed Overexpressed PTTG1 results in chromosome chromatin. PTTG1-null cell proliferation was more instability and aneuploidy, which has been suggested sensitive to Aurora-A knock down and to Aurora kinase as a mechanism underlying PTTG1 transforming Inhibitor III treatment.
    [Show full text]
  • (PTTG1IP/PBF) Predicts Breast Cancer Survival
    Repo et al. BMC Cancer (2017) 17:705 DOI 10.1186/s12885-017-3694-6 RESEARCHARTICLE Open Access PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival Heli Repo1* , Natalia Gurvits1, Eliisa Löyttyniemi2, Marjukka Nykänen3, Minnamaija Lintunen1, Henna Karra4, Samu Kurki5, Teijo Kuopio3, Kati Talvinen1, Mirva Söderström1 and Pauliina Kronqvist1 Abstract Background: PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. Methods: A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival. Results: In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p =0.02). However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052). Conclusions: PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk of breast cancer death, resulting in up to 14-year survival difference in our material. Keywords: PTTG1IP, PBF, Immunohistochemistry, Breast cancer, Prognosis Background nucleus, allowing the interaction between separase and Pituitary tumour transforming gene 1 interacting pro- securin [1].
    [Show full text]
  • Mouse VDR / NR1I1 Protein (His Tag)
    Mouse VDR / NR1I1 Protein (His Tag) Catalog Number: 51106-M08B General Information SDS-PAGE: Gene Name Synonym: Nr1i1 Protein Construction: A DNA sequence encoding the mouse VDR (P48281) (Met1-Ser422) was fused with a polyhistidine tag at the C-terminus. Source: Mouse Expression Host: Baculovirus-Insect Cells QC Testing Purity: > 80 % as determined by SDS-PAGE Endotoxin: Protein Description < 1.0 EU per μg of the protein as determined by the LAL method VDR (vitamin D(1,25- dihydroxyvitamin D3)receptor), also known as NR1I1, Stability: belongs to the NR1I family, NR1 subfamily. It is composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ℃ Samples are stable for up to twelve months from date of receipt at -70 ligand-binding domain. Vitamin D receptors (VDRs) are members of the NR1I family, which also includes pregnane X (PXR) and constitutive Met Predicted N terminal: androstane (CAR) receptors, that form heterodimers with members of the Molecular Mass: retinoid X receptor family. VDRs repress expression of 1alpha-hydroxylase (the proximal activator of 1,25(OH)2D3) and induce expression of the The recombinant mouse VDR consists of 432 amino acids and has a 1,25(OH)2D3 inactivating enzyme CYP24. Also, it has recently been calculated molecular mass of 49.2 kDa. The recombinant protein migrates identified as an additional bile acid receptor alongside FXR and may as an approximately 55 kDa band in SDS-PAGE under reducing conditions. function to protect gut against the toxic and carcinogenic effects of these endobiotics. VDR is expressed in the intestine, thyroid and kidney and has Formulation: a vital role in calcium homeostasis.
    [Show full text]
  • Review Vitamin D in Neurological Diseases: a Rationale for a Pathogenic Impact
    Review Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact Rita Moretti, Maria Elisa Morelli and Paola Caruso * Neurology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Strada di Fiume, 447, 34149, Trieste, Italy; [email protected] (R.M.); [email protected] (M.E.M.) * Correspondence: [email protected] Received: 27 June 2018; Accepted: 26 July 2018; Published: 31 July 2018 Abstract: It is widely known that vitamin D receptors have been found in neurons and glial cells, and their highest expression is in the hippocampus, hypothalamus, thalamus and subcortical grey nuclei, and substantia nigra. Vitamin D helps the regulation of neurotrophin, neural differentiation, and maturation, through the control operation of growing factors synthesis (i.e., neural growth factor [NGF] and glial cell line-derived growth factor (GDNF), the trafficking of the septohippocampal pathway, and the control of the synthesis process of different neuromodulators (such as acetylcholine [Ach], dopamine [DA], and gamma-aminobutyric [GABA]). Based on these assumptions, we have written this review to summarize the potential role of vitamin D in neurological pathologies. This work could be titanic and the results might have been very fuzzy and even incoherent had we not conjectured to taper our first intentions and devoted our interests towards three mainstreams, demyelinating pathologies, vascular syndromes, and neurodegeneration. As a result of the lack of useful therapeutic options, apart from the disease- modifying strategies, the role of different risk factors should be investigated in neurology, as their correction may lead to the improvement of the cerebral conditions. We have explored the relationships between the gene-environmental influence and long-term vitamin D deficiency, as a risk factor for the development of different types of neurological disorders, along with the role and the rationale of therapeutic trials with vitamin D implementation.
    [Show full text]
  • Nuclear Localization of PTTG1 Promotes Migration and Invasion of Seminoma Tumor Through Activation of MMP-2
    Nuclear Localization of PTTG1 Promotes Migration and Invasion of Seminoma Tumor Through Activation of MMP-2. Emanuela Teveroni International Scientic Institute "Paul VI", ISI, Fondazione Policlinico "A.Gemelli" IRCCS Fiorella Di Nicuolo International Scientic Institute "Paul VI", ISI, Fondazione Policlinico "A.Gemelli" IRCCS Giada Bianchetti Department of Neuroscience, section of Biophysics, Università Cattolica del Sacro Cuore Alan L. Epstein Department of Pathology, Keck school of medicine, University of Southern California, Los Angeles Giuseppe Grande International Scientic Institute "Paul VI", ISI, Fondazione Policlinico "A.Gemelli" IRCCS Giuseppe Maulucci Department of Neuroscience, section of Biophysics, Università Cattolica del Sacro Cuore Marco De Spirito Università Cattolica del Sacro Cuore: Universita Cattolica del Sacro Cuore Alfredo Pontecorvi Division of Endocrinology, Fondazione policlinico "A.Gemelli" IRCCS Domenico Milardi Division of Endocrinology, Fondazione policlinico "A.Gemelli" IRCCS Francesca Mancini ( [email protected] ) International Scientic Institute "Paul VI", ISI, Fondazione Policlinico 'A. Gemelli' IRCCS, Rome, Italy https://orcid.org/0000-0002-2459-8815 Research Keywords: PTTG1, seminoma cell lines, testicular cancer, PBF, MMP-2, invasiveness Posted Date: December 15th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-125309/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/53 Abstract Background: Seminoma is the most common subtype of testicular germ cell tumors (TGCTs) and its molecular patterns have not been fully claried. The pituitary tumor-transforming gene 1 (PTTG1) is a securin, inhibitor of premature sister chromatid segregation during mitosis and is overexpressed in many cancers. PTTG1 shows the ability to sustain the invasiveness of several cancer types through its transcriptional activity.
    [Show full text]
  • Sp1 Transcription Factor: a Long-Standing Target in Cancer Chemotherapy
    Sp1 transcription factor: A long-standing target in cancer chemotherapy Carolina Vizcaíno, Sylvia Mansilla and José Portugal* Instituto de Biología Molecular de Barcelona, CSIC, Parc Científic de Barcelona, E-08028 Barcelona, Spain *to whom correspondence should be addressed: Dr. José Portugal, Instituto de Biología Molecular de Barcelona, CSIC, Parc Científic de Barcelona, Baldiri Reixac, 10; E-08028 Barcelona, Spain. Phone: +34 93 403 4959, FAX: +34 93 403 4979, E-mail: [email protected] 1 ABSTRACT Sp1 (Specificity protein 1) is a well-known member of a family of transcription factors that also includes Sp2, Sp3 and Sp4, which are implicated in an ample variety of essential biological processes and have been proven important in cell growth, differentiation, apoptosis and carcinogenesis. Sp1 activates the transcription of many cellular genes that contain putative CG- rich Sp-binding sites in their promoters. Sp1 and Sp3 proteins bind to similar, if not the same, DNA tracts and compete for binding, thus they can enhance or repress gene expression. Evidences exist that the Sp-family of proteins regulates the expression of genes that play pivotal roles in cell proliferation and metastasis of various tumors. In patients with a variety of cancers, high levels of Sp1 protein are considered a negative prognostic factor. A plethora of compounds can interfere with the trans-activating activities of Sp1 and other Sp proteins on gene expression. Several pathways are involved in the down-regulation of Sp proteins by compounds with different mechanisms of action, which include not only the direct interference with the binding of Sp proteins to their putative DNA binding sites, but also promoting the degradation of Sp protein factors.
    [Show full text]